Trials Sponsors Conditions Drugs Pricing

Conditions

Differentiated Thyroid Cancer (DTC)

Outcome Measures

Primary Outcomes (1)

Recruitment rate
Successful recruitment rate of all eligible patients: the percentage of eligible patients who agree to participate out of all eligible patients screened and its 95% confidence interval.
From enrolment for 9 months

Secondary Outcomes (2)

Percentage of participants in PDA arm who use the PDA-TC
From enrolment for 9 months
Difference of the overall score of the decisional conflict scale
From enrolment for 9 months

Study Arms (2)

Control arm

Control arm will follow standard clinical practice. Patients with newly diagnosed low-risk DTC will be recruited to attend two outpatient clinical appointments as part of their standard thyroid cancer care pathway. In the initial consultation, thyroid cancer clinicians will discuss with patient the available treatment options (i.e. total thyroidectomy and hemithyroidectomy) for the low-risk DTC and their associated risks and benefits. Instead of making the treatment decision straight away, patients will be allowed to a week to digest the information and to consider the options. A week later, patients will return for the second outpatient consultation where they will decide on the treatment with their clinicians.

PDA arm

In the PDA arm, the study procedure will be the same as in control arm except that the PDA-TC pamphlet will be introduced to patient after the first outpatient clinical consultation. Patients are allowed to take the PDA-TC home to read and digest the information before returning for their second outpatient consultation a week later. The data collection timing and measures in the PDA arm will remain the same as in the control arm.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients will be identified from the Thyroid MDT lists at the respective study centres by the local head and neck surgical team (patient's direct care team)

You may qualify if:

Aged over 18

Sponsors & Collaborators

Wrightington, Wigan and Leigh NHS Foundation Trust
Othercollaborator
Royal Marsden NHS Foundation Trust
Otherlead

Study Sites (1)

Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust

Wigan, United Kingdom

RECRUITING

Wanding YangCONTACT02073528171 Wanding.Yang@rmh.nhs.uk

Central Study Contacts

Wanding Yang

CONTACT

02073528171 Wanding.Yang@rmh.nhs.uk

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: CROSS SECTIONAL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 3, 2024

First Posted

March 4, 2025

Study Start

June 19, 2024

Actual (reported)

Primary Completion

October 1, 2025

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

The EMIRATES Study

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Control arm

PDA arm

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (2)

Control arm

PDA arm

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations